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and provides a clear example of how 
epidemiologic baseline information 
on virus host range and tropism in ani-
mals may provide indications for the 
presence of similar viruses in the same 
organ system of humans. To clarify 
the epidemiology and pathogenicity of 
picobirnaviruses in humans, addition-
al surveillance should be carried out in 
persons with and without respiratory 
and enteric disease.
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To the Editor: The metallo-
β-lactamase (MBL) group of 
enzymes inactivates many β-lactam 
antimicrobial drugs. First identifi ed 
from a Klebsiella pneumoniae strain 
recovered from a patient hospitalized 
in India, the New Delhi metallo-β-
lactamase-1 (NDM-1), particularly 
in Enterobacteriaceae, is now the 
focus of worldwide attention (1). 
Whereas India and Pakistan were 
considered as the main reservoirs of 
the blaNDM-1 gene (2) that produces 
this MBL, several NDM-1–producing 
Enterobacteriaceae isolates have been 
reported from the Balkan states and 
the Middle East, suggesting that those 
areas might be secondary reservoirs 
(2).
Since 2010, 3 NDM-1 point-
mutation variants have been described 
(3–5). The fi rst variant, NDM-2, was 
identifi ed from an Acinetobacter 
baumannii isolate collected from a 
patient transferred from a hospital in 
Egypt to Germany (4). Subsequently, 
a clonal dissemination of NDM-
2–producing A. baumanni was 
described in Israel (6). The second 
variant, NDM-4, which was identifi ed 
in Escherichia coli from a patient 
hospitalized in India, possessed 
a higher carbapenemase activity 
compared with NDM-1 (5). The most 
recent variant, NDM-5, was identifi ed 
in E. coli from a patient who had a 
history of hospitalization in India (3).
As recommended for the detection 
of carbapenemase producers (7), a 
rectal swab specimen was collected 
from a patient transferred from 
Cameroon to France. The E. coli strain 
FEK was isolated from the specimen. 
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He had been hospitalized for 1 
month in Douala for an infl ammatory 
syndrome associated with a kidney 
failure before his transfer to Paris. No 
history of travel in India was reported 
for this patient. Susceptibility testing 
was performed by disk diffusion 
assay (Sanofi -Diagnostic Pasteur, 
Marnes-la-Coquette, France), and 
results were interpreted according to 
the updated guidelines of the Clinical 
and Laboratory Standards Institute 
(Wayne, PA, USA; www.clsi.org). The 
MICs were determined by using Etest 
(bioMérieux, La Balmes-Les-Grottes, 
France) on Mueller-Hinton agar at 
37°C. 
E. coli FEK was fully resistant 
to all β-lactam antimicrobial drugs, 
including imipenem, meropenem, 
ertapenem, and doripenem (MICs 
>32 mg/L for all carbapenems). 
This isolate was also resistant to 
aminoglycosides, except amikacin, 
and to fl uoroquinolones. We 
performed PCR amplifi cation 
followed by sequencing on whole-cell 
DNA, as described (8). We identifi ed 
the blaNDM-4, blaCTX-M-15, and blaOXA-1 
genes. E. coli FEK also harbored the 
aacA4 gene encoding the AAC(6′)-Ib 
acetyltransferase that confers high-
level resistance to aminoglycosides, 
except amikacin. Results of 
multilocus sequence typing analysis 
performed as described (5) showed 
that the isolate belonged to sequence 
type (ST) ST405. Identifi cation of 
this ST type among NDM-producing 
E. coli, compared with NDM-4– and 
NDM-5–producing E. coli in ST648, 
demonstrated that the spread of NDM-
4 occurred among unrelated E. coli 
clonal backgrounds (3,5).
Plasmid DNA of E. coli FEK was 
extracted and analyzed as described 
(5). A single, ≈120-kb plasmid was 
identifi ed. Direct transfer of the 
β-lactam resistance marker into E. coli 
J53 was attempted by liquid mating-
out assays at 37°C. With the exception 
of the aminoglycoside amikin, 
transconjugants from E. coli were 
resistant to β-lactam antimicrobial 
drugs. MICs of imipenem, mero-
penem, ertapenem, and doripenem 
were 6, 3, 6, and 4 mg/L, respectively. 
The transconjugants harbored an 120-
kb plasmid carrying blaNDM-4 and the 
blaCTX-M-15, blaOXA-1, and aacA4 genes. 
We performed PCR-based replicon 
typing as described (5) and showed 
that this blaNDM-4–positive plasmid 
belonged to the IncFIA incompatibility 
group. The IncF incompatibility 
group was previously reported to be 
associated with blaNDM-4 and blaNDM-5 
(3,5).
By analyzing genetic structures 
surrounding the blaNDM-4 gene, 
performed by PCR mapping as 
described (8), we identifi ed insertion 
sequence ISAba125 upstream and 
the bleomycin resistance gene bleMBL 
downstream of the blaNDM-4 gene. The 
same genetic environment has been 
observed for most NDM-1–positive 
enterobacterial isolates (8). We showed 
in previous research that expression of 
bleMBL conferred high-level resistance 
to bleomycin and bleomycin-like 
molecules (9); accordingly, the E. coli 
clinical isolate and its transconjugant 
were highly resistant to bleomycin 
(MIC >512 μg/mL) (9). 
The patient had a history of 
Hodgkin lymphoma treated by 8 
sessions of bleomycin chemotherapy 
1 year before his hospitalization. This 
anticancer drug is widely distributed 
throughout the body following 
intravenous administration, and 
plasmatic concentrations increase 
in proportion with the increase of 
the dose (10). Because the patient 
was successively treated with 30 
mg of bleomycin, the serum levels 
achieved (≈2–5 mg/mL) might 
have contributed to selection of the 
bleMBL gene. Similarly, the multiple 
courses of antibacterial drug therapy 
administered in Cameroon (including 
carbapenems) could have contributed 
to selection of the blaNDM-4 gene.
By culturing rectal swab samples 
from the patient, we identifi ed fecal 
carriage of E. coli carrying a plasmid-
encoded blaNDM-1 gene. That strain had 
a distinct ST type (ST5) compared 
with the index strain. The plasmid 
carrying the blaNDM-1 gene with the 
blaOXA-1 and aacA4 genes belonged to 
the IncFIA incompatibility group.
β-Lactamase NDM-4 displaying 
increased carbapenemase activity 
compared with NDM-1 was described 
in a patient hospitalized in India 
(5). This study shows that NDM-
4 producers are also present in 
Africa; specifi cally, in the highly 
populated city of Douala, providing 
an environment that may promote 
the dissemination of those strains. 
We showed that the same patient was 
carrying strains expressing 2 NDM 
variants, possibly indicating ongoing 
evolution of NDM variants.
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To the Editor: Infection with 
Salmonella enterica serovar Agbeni 
is rare. In Canada, it was reported 8 
times during 2000–2010 and never 
in the province of British Columbia 
(2011 population 4.5 million) (Public 
Health Agency of Canada, unpub. 
data). In June 2011, an outbreak of 
S. enterica ser. Agbeni affecting 8 
persons was identifi ed in British 
Columbia; pulsed-fi eld gel 
electrophoresis patterns for all isolates 
were identical. Although no specifi c 
source was identifi ed, 2 features were 
noted: 1) diagnosis through urine 
specimens for 3 of 8 persons and 2) a 
longer than typical incubation period 
for Salmonella spp. infection.
In British Columbia, public 
health authorities interview all 
reported Salmonella spp.–infected 
persons by using a standard 
questionnaire (www.bccdc.ca/dis-
cond/CDSurveillanceForms) to 
collect information about potential 
exposures during the 3 days before 
date of illness onset. Seven of the 
ill persons in British Columbia had 
attended the same wedding on May 
14, 2011, which was outside the 3-day 
period about which they were asked. 
The person with the earliest reported 
case (May 16) was not associated 
with the wedding or with the other ill 
persons.
We reviewed wedding food 
sources and preparation. The 7 
persons with wedding-associated 
illness were reinterviewed by using 
a menu-specifi c questionnaire; no 
obvious food source was implicated. 
The fi rst wedding guest to be reported 
with enteric symptoms was visiting 
from outside British Columbia and 
had assisted with food preparation. In 
April and May 2011, fi ve persons from 
the same jurisdiction outside British 
Columbia in which this wedding guest 
resided were identifi ed with S. enterica 
ser. Agbeni infection; isolates from 
these persons had the same pulsed-
fi eld gel electrophoresis pattern as 
those in British Columbia. Also, the 
ill person who was not associated with 
the wedding had traveled to that same 
jurisdiction before onset of symptoms. 
The original source of infection was 
probably outside of British Columbia.
Average age of the 8 ill persons 
was 52.8 years (range 21–82 years). 
Six were men. One person reported 
hospital admission. No underlying 
conditions were documented in any of 
the 8 ill persons.
Culture results of urine samples 
were positive for 3 (38%) of the 8 ill 
persons; feces were not tested. All 3 
persons had symptoms of urinary tract 
infection (UTI), and 2 had fever. All 
were men and were the oldest persons 
reported. Two had gastrointestinal 
(GI) symptoms before UTI symptoms. 
For 1 person, the interval between 
onset of GI and UTI symptoms was 
15 days.
Approximately 1% of non-
typhoidal Salmonella spp. infections 
are detected in urine (1,2). In British 
Columbia, ≈3% of Salmonella 
isolates submitted to the reference 
laboratory are isolated from urine 
(British Columbia Centre for Disease 
Control’s Public Health Microbiology 
and Reference Laboratory, unpub. 
data). Salmonella spp. are more often 
recovered from urine in adults >60 
years of age, children (2,3), and female 
patients (2,4). Immunocompromising 
conditions and urinary tract structural 
abnormalities also are risk factors for 
isolating the organism in urine (2,3). 
Also, certain Salmonella serogroups 
or serotypes are more likely than 
others to be isolated from urine 
(2,3). GI symptoms concurrent with 
or preceding UTI are rare (4,5). We 
found no literature to suggest whether 
S. enterica ser. Agbeni is more likely 
to cause systemic illness or UTI. The 
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